digistain
@digistain
Followers
83
Following
28
Media
64
Statuses
99
DIGISTAIN® – Revolutionary breast cancer risk profiling technology #breastcancer #breastcancerdiagnosis #cancerdiagnosis #digistain #digitalhealth #cancer
UK
Joined April 2022
We were thrilled to showcase Digistain at #BIGOSA2025 with Key Oncologics, where we had some excellent conversations and gained valuable insights. Here we reaffirm our commitment to support improved #cancercare in South Africa and look forward to future opportunities.
0
0
1
We are proud to announce that following the official launch of Digistain in South Africa last month, the technology has already been successfully integrated into routine clinical practice by local oncologists. #HealthcareInnovation #cancerresearch #breastcancerawareness
0
0
2
Congratulations to @digistain, Winners of the 2025 EIT Health Open Innovation Breast Cancer Challenge! #OpenInnovation #BreastCancerCare #Oncology #HealthInnovation #EITHealth @EITHealth
0
1
5
Dr. Hemmel Amrania, CEO of Digistain, will be delivering a keynote at the AI4Health.Cro Consortium Annual Conference today, April 8th, 2025, at the Hotel Zonar, Zagreb. #AI4Health #CancerDiagnostics #MedTech #Oncology #AI #HealthcareInnovation #BreastCancer #Zagreb #Digistain
0
0
0
We’re excited to highlight some of the key features of the Digistain test that could make a real difference for you or your patients. To learn more about how Digistain could help, visit our website: https://t.co/tVeacZZqfN
#BreastCancerAwareness #RiskStratification #CancerCare
0
1
1
We're excited to share that Digistain is now being used by patients covered by one of the top four health insurers in the U.S. A big thank you to our incredible team, partners, and supporters who make this progress possible! #CancerDiagnostics #PrecisionMedicine
0
1
3
Delighted to have Dr. Mel Valerie Cruz-Ordinario present to doctors at St. Luke’s Medical Center Quezon City, Philippines, sharing her specialist insight on the benefits of Digistain for precision risk stratification in breast cancer patients.
0
0
0
This World Cancer Day 2025, we proudly reaffirm our commitment to transforming cancer care through innovation and compassion.
0
0
0
A massive honour to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London. #CancerCare #PrecisionMedicine #Digistain #MedicalResearch #GlobalHealth #CancerDiagnostics
0
0
2
We’re proud to show the incredible work being done by Shawn Chong and team with dedicated doctors in Indonesia who are supporting us in our mission to help close the gap in healthcare inequalities globally by providing an accessible solution for breast cancer risk stratification.
0
0
1
Following our partnership with Deloitte, we had the privilege of speaking with Senior Manager Roberto Vittandi, who shared his insights on Digistain and it's potential. We believe collaboration drives innovation, and we're excited to be on this journey together!
0
0
0
Watch Professor Charles Coombes & Dr. Hemmel Amrania discuss the future of #RiskStratification in #BreastCancer and how Digistain is making it quicker & more accessible for patients everywhere. #CancerCare #HealthTech #Oncology
https://t.co/M9LJnlPyws
0
0
0
Check out our 2nd abstract poster from #SABCS2024: "Analytical Validity of the Digistain Test in the Face of Variable Fixation Times." Read the full abstract here: https://t.co/lD4upuiTbG
0
0
0
Had a great time at #SABCS2024 with our clinical board members, Dario Francescatti & Carlo Palmieri! Excited to share our data and continue our mission to make cancer diagnostics faster and more accessible to all. #CancerDiagnostics #Digistain #CancerResearch #Oncology
0
0
2
We were honored to host Malaysia's Health Minister, Dr. Dzulkefly Ahmad, at the Digistain lab. His visit marks a key step in advancing nationwide access to transformative breast cancer diagnostics. We look forward to driving meaningful healthcare impact together. #breastcancer
0
0
0
We’re proud to share that our landmark clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal's top-performing articles, ranked in the 97th percentile for popularity. https://t.co/lmSiSUtWUS
pmc.ncbi.nlm.nih.gov
Digistain Index (DI), measured using an inexpensive mid-infrared spectrometer, reflects the level of aneuploidy in unstained tissue sections and correlates with tumor grade. We investigated whether...
0
0
0
Our recently published validation of a novel and effective methodology to support therapy decisions in early breast cancer demonstrated e equivalent performance to existing solutions in over 800 patients. But radically faster and more accessible.
link.springer.com
Breast Cancer Research and Treatment - Digistain Index (DI), measured using an inexpensive mid-infrared spectrometer, reflects the level of aneuploidy in unstained tissue sections and correlates...
0
2
3
Complexly novel way to assess risk of recurrence in ER+/HER2- early breast cancer using mid-infrared spectrometer @digistain It’s simple,quick & can be done locally. First data using Nottinghan series, shows it can separate patients into low vs high risk. More studies underway.
0
2
10
Latest validating #research demonstrating @Digistain accurate prediction of #breastcancer recurrence risk published with @SpringerNature in the Journal of Breast Cancer Research & Treatment. https://t.co/nCaudFXTfa
#oncology #pathology #innovation
0
1
3